TOSK, INC.
Small molecule inhibitors targeting oncogenic kRAS mutations (G12V) to restore growth pathway control in cancer cells
- Sector
- Biotech
- Headquarters
- Mountain View, CA
- Latest Form D
- $100K, Sep 2022
- Total capital
- $2.9M
- Federal grants
- $2M
- 2 awards · 2017–2018
- Rank in peer group#38 of 326
- Private capital raised
- $916K
- 3 Form D · last Sep 2022
- 49 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 15
- 25 pending · first 2016
- Rank in peer group#14 of 326
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$100K
- Federal grantHealth and Human S · Phase II · Suppressors of kRAS Activity Discovered Using a Fruit Fly-based In-vivo Screen$956K
- Federal grantHealth and Human S · Phase II · Suppressors of kRAS Activity Discovered Using a Fruit Fly-based In-vivo Screen$1M
- Private capital raisedForm D · SEC · 2nd filing$18K
- Private capital raisedForm D · SEC · 1st filing$798K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#38 · top 12%
- Granted patents#14 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Brian FrenzelExecutive OfficerNamed in SEC Form D filings
- CHARLES GARVINDirectorNamed in SEC Form D filings
- HAROLD CROWDirectorNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 40- GrantedUridine Phosphorylase (UPase) Inhibitors for Treatment of Liver ConditionsUSPTOUS 12,667,571
- GrantedModulators of RAS GTPaseUSPTOUS 12,528,796
- GrantedMethods and Compositions for Reducing Radiation Induced ToxicityUSPTOUS 12,508,265
Show all 40 patent records
- Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver ConditionsJun 30, 2026 · US 12,667,571Granted
- Modulators of RAS GTPaseJan 20, 2026 · US 12,528,796Granted
- Methods and Compositions for Reducing Radiation Induced ToxicityDec 30, 2025 · US 12,508,265Granted
- Modulators of RAS GTPaseDec 2, 2025 · US 12,486,255Granted
- Methods and Compositions for Maximizing the Prevention and/or Reduction of Various Maladies and Drug Side-Effects Using UridineSep 23, 2025 · US 12,419,893Granted
- Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary DiseaseJul 10, 2025 · Application 19016423Pending
- Methods and Compositions for Treating MucositisFeb 13, 2025 · Application 18825720Pending
- Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary DiseaseJan 14, 2025 · US 12,194,043Granted
- Heteroaryl Modulators of RAS GTPaseDec 31, 2024 · US 12,180,220Granted
- Methods and Compositions for Treating MucositisOct 8, 2024 · US 12,109,222Granted
- Modulators of RAS GTPaseApr 2, 2024 · US 11,945,803Granted
- Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary DysfunctionMar 21, 2024 · Application 18241501Pending
- Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver ConditionsSep 20, 2022 · US 11,446,303Granted
- Pyrazolopyrimidine Modulators of RAS GTPaseJul 19, 2022 · US 11,390,626Granted
- Small Molecule Modulators of RAS GTPaseApr 14, 2022 · Application 17484735Pending
- Non-Mammalian RAS Transgenic Animal ModelDec 17, 2020 · Application 16854118Pending
- Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the SameOct 13, 2020 · US RE48,253Granted
- Non-mammalian Ras Transgenic Animal ModelMay 26, 2020 · US 10,660,318Granted
- Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the SameOct 18, 2016 · US 9,468,613Granted
- Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the SameJul 5, 2016 · US 9,382,287Granted
- Modulators of RAS GTPaseApplication 62715505Pending
- Non-mammalian Ras Transgenic Animal ModelApplication PCTUS2014051746Pending
- Non-mammalian Ras Transgenic Animal ModelApplication 61867979Pending
- Reduced Toxicity Methotrexate Formulations And Methods For Using The SameApplication PCTUS2005032046Pending
- Methods And Compositions For Use In Homologous Recombination In Plant CellsApplication PCTUS2004016798Pending
- Methods And Compositions For Use In Homologous RecombinationApplication PCTUS2003013444Pending
- Reduced Toxicity Cisplatin Formulations And Methods For Using The SameApplication PCTUS2002029669Pending
- Animal Integration Vector And Methods For Its UseApplication PCTUS2002029999Pending
- Uridine Phosphorylase Inhibitors To Prevent Or Treat Drug-induced Pulmonary DysfunctionApplication PCTUS2022018942Pending
- Uridine Phosphorylase Inhibitors To Treat Or Prevent Pulmonary DiseaseApplication PCTUS2021040290Pending
- Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary DysfunctionApplication 63157246Pending
- Heteroaryl Modulators of RAS GTPaseApplication 63091450Pending
- Small Molecule Modulators of RAS GTPaseApplication 63091447Pending
- Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary DiseaseApplication 63048850Pending
- Uridine Phosphorylase (upase) Inhibitors For Treatment Of Liver ConditionsApplication PCTUS2020038353Pending
- Modulators Of Ras GtpaseApplication PCTUS2020027985Pending
- Pyrazolopyrimidine Modulators Of Ras GtpaseApplication PCTUS2020015343Pending
- Methods And Compositions For Reducing Fluorouracil Induced ToxicityApplication PCTUS2019046375Pending
- Methods And Compositions For Treating MucositisApplication PCTUS2019046386Pending
- Methods And Compositions For Reducing Radiation Induced ToxicityApplication PCTUS2019046373Pending
Related companies, and why
- Flux Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
- BINARY GENOMICS, INC.Similar federal contract value in Biotech · null in contracts
- Cavatar LLCSimilar federal contract value in Biotech · null in contracts
- DOOR PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts
- KINASENSE, LLCSimilar federal contract value in Biotech · null in contracts
- PARION SCIENCES, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .